Publications 2016-2024
Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model. van Nieuwenhuijzen N, Cuenca M, Abbink L, Jak M, Peperzak V, Minnema MC. EJHaem. 2023 Nov 29;5(1):141-146. PMID: 38406516
Bridging the gap between scientific discoveries and clinical application at the Utrecht Science Park. Peperzak V, Coquet JM. Immunol Cell Biol. 2024 Apr;102(4):232-234. PMID: 38058197
Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients. Beltrán-Visiedo M, Jiménez-Alduán N, Díez R, Cuenca M, Benedi A, Serrano-Del Valle A, Azaceta G, Palomera L, Peperzak V, Anel A, Naval J, Marzo I. Mol Oncol. 2023 Dec;17(12):2507-2525. PMID: 37704591
Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma. Greve P, Beishuizen A, Hagleitner M, Loeffen J, Veening M, Boes M, Peperzak V, Diez C, Meyer-Wentrup F. Front Immunol. 2023 Jul 31;14:1229558. PMID: 37583696
Serpin B9 controls tumor cell killing by CAR T cells. Kimman T, Slomp A, Martens A, Grabherr S, Li S, van Diest E, Meeldijk J, Kuball J, Minnema MC, Eldering E, Bovenschen N, Sebestyén Z, Peperzak V. J Immunother Cancer. 2023 Mar;11(3):e006364. PMID: 36931661
Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma. Spaan I, van Nieuwenhuijzen N, Kimman T, Rockx-Brouwer D, Tieland RG, Maurice MM, Minnema MC, Raymakers RA, Peperzak V. Blood Adv. 2023 Apr 11(7):1103-1107. PMID: 36459495
Inhibitory pattern recognition receptors. Rumpret M, von Richthofen HJ, Peperzak V, Meyaard L. J Exp Med. 2022 Jan 3;219(1):e20211463. PMID: 34905019
Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition. Cuenca M, Van Nieuwenhuijzen N, Moesbergen LM, Bloem A, Minnema MC, Peperzak V. Haematologica. 2022 Apr 1;107(4):980-983. PMID: 34879645
Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1. Spaan I, van de Stolpe A, Raymakers RA, Peperzak V. Cancers (Basel). 2021 Sep 17;13(18):4668. PMID: 34572895
Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma. Spaan I, Timmerman LM, Kimman T, Slomp A, Cuenca M, van Nieuwenhuijzen N, Moesbergen LM, Minnema MC, Raymakers RA, Peperzak V. Blood Adv. 2021 Jun 22;5(12):2593-2607. PMID: 34152396
Advances and Perspectives in the Treatment of B-Cell Malignancies. Cuenca M, Peperzak V. Cancers (Basel). 2021 May 8;13(9):2266. PMID: 34066840
Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells. Slomp A, Moesbergen LM, Eldering E, Kersten MJ, Minnema MC, Peperzak V. Cell Death Dis. 2021 Mar 3;12(3):229. PMID: 33658484
Upcoming immunotherapeutic combinations for B-cell lymphoma. Greve P, Meyer-Wentrup FAG, Peperzak V, Boes M. Immunother Adv. 2021 Feb 9;1(1):ltab001. PMID: 35919738
Endochondral Bone Regeneration by Non-autologous Mesenchymal Stem Cells. Longoni A, Pennings I, Cuenca Lopera M, van Rijen MHP, Peperzak V, Rosenberg AJWP, Levato R, Gawlitta D. Front Bioeng Biotechnol. 2020 Jul 9;8:651. PMID: 32733861
Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Slomp A, Moesbergen LM, Gong JN, Cuenca M, von dem Borne PA, Sonneveld P, Huang DCS, Minnema MC*, Peperzak V*. Blood Adv. 2019 Dec 23;3(24):4202-4214. PMID: 31856269
Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma. Slomp A, Peperzak V. Front Oncol. 2018 Nov 20;8:533. PMID: 30524962
Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential. Spaan I, Raymakers RA, van de Stolpe A, Peperzak V. J Hematol Oncol. 2018 May 18;11(1):67. PMID: 29776381
From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells. van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. Cancer Res. 2018 May 15;78(10):2449-2456. PMID: 29703720
DNA-binding of the Tet-transactivator curtails antigen-induced lymphocyte activation in mice. Ottina E, Peperzak V, Schoeler K, Carrington E, Sgonc R, Pellegrini M, Preston S, Herold MJ, Strasser A, Villunger A. Nat Commun. 2017 Oct 18;8(1):1028. PMID: 29044097
c-Myb Regulates the T-Bet-Dependent Differentiation Program in B Cells to Coordinate Antibody Responses. Piovesan D, Tempany J, Di Pietro A, Baas I, Yiannis C, O'Donnell K, Chen Y, Peperzak V, Belz GT, Mackay CR, Smyth GK, Groom JR, Tarlinton DM, Good-Jacobson KL. Cell Rep. 2017 Apr 18;19(3):461-470. PMID: 28423310
Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. Peperzak V, Slinger E, Ter Burg J, Eldering E. Cell Death Differ. 2017 Jan;24(1):111-119. PMID: 27689871
MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL. Vikström IB Slomp A, Carrington EM, Moesbergen LM, Chang C, Kelly GL, Glaser SP, Jansen JHM, Leusen JHW, Strasser A, Huang DCS, Lew AM, Peperzak V*, Tarlinton DM*. Cell Death Dis. 2016 Aug 25;7(8):e2345. PMID: 27560714